Sign up USA
Proactive Investors - Run By Investors For Investors

The Hydropothecary Corp has great potential in Quebec, says Eight Capital

It initiates with a 'buy' stance and C$3.50 target price, which is a fair way from then current share price of C$1.46..
The Hydropothecary Corp has great potential in Quebec, says Eight Capital
The firm is currently Quebec's only fully licensed cannabis producer (cultivation and sales)

Broker Eight Capital is bullish on The Hydropothecary Corp (CVE:THCX), which  is currently Quebec's only  fully licensed cannabis producer (cultivation and sales) and has started covering the stock.

It initiates with a 'buy' stance and C$3.50 target price, which is a fair way from then current share price of C$1.46.

Analyst Daniel Pearlstein says the firm should get "first crack" at supplying the regional recreational market.

"With Quebec's population now over 8 million inhabitants, being the sole fully Licensed Producer in the province could prove a lucrative opportunity," he suggests.

The group is well positioned to supply whichever method of distribution the Quebec government decides upon - likely through government-run stores via Société des alcools du Québec (SAQ), he notes.

It is also  undertaking a 250,000 sq ft expansion that would include a greenhouse, GMP laboratories, offices and warehousing.

This is expected to take the firm's annual production capacity to 25,000 kg, says the analyst, and be completed by summer 2018.

The company has commercialized two unique products within the ACMPR (medical cannabis access) rules, including the industry's only orally administered cannabis oil spray.

"As the rules and regulations on derivative products evolve, we believe LPs will be allowed to manufacture a number of the products currently available in more mature cannabis markets in the US for both the medical and recreational markets," says Pearlstein.

"We believe that product derivatives of the dried flower will be increasingly adopted by the medical community."

The broker's price target is based on a multiple of six times' 2021 estimated EBITDA (underlying earnings), implying a 44% return from the last close.

View full THCX profile View Profile

Related Articles

researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors
woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use